Trial Profile
A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Folinic acid; Mesna; Methotrexate; Vincristine
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms Window I
- 12 Dec 2023 Results assessing Six Years Follow up of Ibrutinib Plus Rituximab Followed By Short Course R-Hyper CVAD/MTX in Patients with Previously Untreated Mantle Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 08 Mar 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2025.
- 08 Mar 2022 Planned primary completion date changed from 30 Jun 2021 to 30 Jun 2025.